A 6-mRNA host response whole-blood classifier trained using patients with non-COVID-19 viral infections accurately predicts severity of COVID-19
Buturovic, L.; Zheng, H.; Tang, B.; Lai, K.; Kuan, W. S.; Gillett, M.; Santram, R.; Shojaei, M.; Almansa, R.; Nieto, J. A.; Munoz, S.; Herrero, C.; Antonakos, N.; Koufargyris, P.; Kontogiorgi, M.; Damoraki, G.; Liesenfeld, O.; Wacker, J.; Midic, U.; Luethy, R.; Rawling, D.; Remmel, M.; Coyle, S.; Liu, Y.; Rao, A. M.; Dermadi, D.; Toh, J.; Jones, L. M.; Donato, M.; Khatri, P.; Giamarellos-Bourboulis, E. J.; Sweeney, T. E.
Show abstract
BackgroundDetermining the severity of COVID-19 remains an unmet medical need. Our objective was to develop a blood-based host-gene-expression classifier for the severity of viral infections and validate it in independent data, including COVID-19. MethodsWe developed the classifier for the severity of viral infections and validated it in multiple viral infection settings including COVID-19. We used training data (N=705) from 21 retrospective transcriptomic clinical studies of influenza and other viral illnesses looking at a preselected panel of host immune response messenger RNAs. ResultsWe selected 6 host RNAs and trained logistic regression classifier with a cross-validation area under curve of 0.90 for predicting 30-day mortality in viral illnesses. Next, in 1,417 samples across 21 independent retrospective cohorts the locked 6-RNA classifier had an area under curve of 0.91 for discriminating patients with severe vs. non-severe infection. Next, in independent cohorts of prospectively (N=97) and retrospectively (N=100) enrolled patients with confirmed COVID-19, the classifier had an area under curve of 0.89 and 0.87, respectively, for identifying patients with severe respiratory failure or 30-day mortality. Finally, we developed a loop-mediated isothermal gene expression assay for the 6-messenger-RNA panel to facilitate implementation as a rapid assay. ConclusionsWith further study, the classifier could assist in the risk assessment of COVID-19 and other acute viral infections patients to determine severity and level of care, thereby improving patient management and reducing healthcare burden.
Matching journals
The top 11 journals account for 50% of the predicted probability mass.